25TH IABCR CONGRESS CONFERENCE: PERSONALIZED BREAST CANCER THERAPY

描述(申请人提供)：本次会议是国际乳腺癌研究协会第25届大会，旨在促进用于测试药物的小鼠模型的开发和使用，以及用于治疗和治愈人类乳腺癌的创新生物学策略。会议将为业界和学术界备受尊敬的国家和国际领导人提供一个论坛。这次会议的目的是建立必要的联系，以促进科学家和工业界之间随后的合作，并鼓励使用这些模型来减轻人类疾病。这次会议承诺通过将这些小组聚集在一起进行有意义的会议和讨论，预示着行业、临床医生和开发模型的科学家之间合作的新纪元。它将回顾各个科学学科的进展，并让参与者接触到新的方法和新的模型，这些方法和模型可能会服务于比之前小鼠研究预期的更广泛的应用。它还将展示该领域如何利用灵敏的活体成像技术，进入新的有希望的治疗干预领域。 这次会议将专门讨论乳腺癌研究中的几个新兴领域。在丹尼斯·斯拉蒙博士的主旨演讲之后，第一节将讨论乳腺癌的病理学和分子图谱。本次会议还将包括乔·格雷博士的全体演讲，他是乳腺癌遗传学领域公认的领导者。第二节将讨论乳腺癌中激活的各种信号转导通路及其作为治疗靶点的潜在效用。第三期会议将集中讨论生长因子和激素受体在乳腺癌发生和发展中的作用。本次会议还将包括肯特·奥斯本博士关于生长因子受体和荷尔蒙之间的串扰概念的全体演讲。第三次会议将涉及肿瘤微环境和癌症干细胞在乳腺癌发生发展中的新角色。本次会议将包括John Condeelis博士关于炎症反应在调节乳腺癌进展中的作用的全体演讲。会议的最后一次会议将讨论乳腺癌治疗中使用的新兴疗法。来自学术、制药和生物技术领域的发言者将占突出地位。会议还将包括A Ullrich博士的全体演讲，他开创了以HER2癌基因为靶点治疗乳腺癌的概念。

DESCRIPTION (provided by applicant): This meeting, the 25th Congress of the International Association for Breast Cancer Research, is designed to foster the development and use of mouse models for testing pharmaceuticals and innovative biological strategies for the treatment and cure of human breast cancer. The meeting will provide a forum for highly regarded national and international leaders in industry and academia. The meeting is designed to establish the contacts necessary to foster subsequent collaborations between scientists and industry and to stimulate the use of the models to alleviate human disease. The meeting promises to herald a new era of cooperation between industry, clinicians, and scientists who develop the models by bringing the groups together for meaningful meetings and discussions. It will review the progress in the various scientific disciplines and expose the participants to new approaches and new models that might serve much wider applications than has been expected from previous murine studies. It will also show how the field is moving into new promising areas of therapeutic interventions, taking advantage of sensitive in vivo imaging techniques. This meeting will specifically address several emerging areas in breast cancer research. Following a keynote lecture from Dr. Dennis Slamon, the first session will deal with the pathology and molecular profiling of breast cancer. This session will also include a plenary lecture from Dr. Joe Gray; an acknowledged leader in area of breast cancer genetics. The second session will deal with various signal transduction pathways activated in breast cancer and their potential utility as therapeutic targets. The third session will focus on the role of growth factor and hormone receptors in the initiation and progression of breast cancer. This session will also include a plenary lecture from Dr. Kent Osborne dealing with the concept of crosstalk between both growth factor receptors and hormones. The third session will involve the emerging roles of tumor microenvironment and cancer stem cell in development of breast cancer. This session will include a plenary lecture from Dr. John Condeelis dealing with the role of inflammatory response in regulating breast cancer progression. The final session of the meeting will deal with the emerging therapies that are used in the treatment of breast cancer. Speakers from both academic and pharmaceutical and biotechnology fields will be prominently represented. The session will also include a plenary lecture from Dr. A Ullrich who pioneered the concept of targeting the HER2 oncogene in the treatment of breast cancer.